All In Biotech

Drug Trial Radar · NCT07939802

A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old

A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adults With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Nov 19, 2026

Primary completion

Sep 19, 2028

Study completion Mar 20, 2029

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about the effects of felzartamab, also known as BIIB148, in adult participants with generalized myasthenia gravis, also known as gMG. This is a type of autoimmune disease that affects the signals sent between nerve cells and the muscles. An autoimmune disease means the body's immune system attacks its own healthy cells. In people with gMG, the body's immune system makes abnormal antibodies that affect the signals that can be sent between the muscle and the nerves at the neuromuscular junction. The neuromuscular junction is where the nerve and muscle connect. The most common antibodies made in gMG are those that target 1 of 2 types of proteins - AchR (acetylcholine receptor) and MuSK (muscle-specific tyrosine kinase). In this study, researchers wanted to learn more about a study drug called felzartamab. Researchers think felzartamab may lower the amount of antibodies against AChR or MuSK and allow signals between muscles and nerves to be sent normally again. The main goal of the study is to compare the effects of felzartamab to a placebo on symptoms and daily living activities in adult participants with gMG. A placebo looks like the study drug but does not contain any medicine. The main question researchers want to answer is: * Does felzartamab increase the ability to perform daily activities after 26 weeks of treatment in participants with AChR antibodies? Researchers will also learn more about: * How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug. * How the body processes felzartamab * How felzartamab affects the participants' disease severity * How many participants' bodies make antibodies against felzartamab after treatment This study will be done as follows: * Participants will join the study after signing an informed consent form, also known as an ICF. * Participants will be screened to check if they can join the study. Participants will then be assigned to a study group based on the type of antibodies they have. * If participants have AChR antibodies, they will be randomly assigned to receive either felzartamab or a placebo. Neither the participants nor the researchers will know if participants are getting the study drug or the placebo. * If participants have MuSK antibodies, they will receive felzartamab. In this group, the participants, study doctor, and study staff know which drug the participant is taking. * Both felzartamab and the placebo will be given as an intravenous (IV) infusion, which involves giving the drug into a vein. * During the study, participants will have regular clinic visits and phone calls. At the visits, participants will have blood and urine samples taken and will also have their overall health checked. The participants will also be asked questions about how they are feeling and how their gMG is affecting their daily lives. * After their last dose, participants will enter a follow-up safety period for more testing and monitoring of their health.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • FelzartamabDrug

    Administered IV

  • PlaceboDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26Time frame: Baseline, Week 26

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.